alexa RNAi-based Cancer Therapeutics: Are we there yet?

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

RNAi-based Cancer Therapeutics: Are we there yet?

RNAi-based therapeutics remains one of the most promising strategies for the effective cancer treatment due to its high target-specificity, precise mechanism of action, greater potency and reduced side effects. Although, tremendous progress and advances have been made in the past few years to develop nanotechnology-based efficient non-viral delivery systems, there are still many hurdles and challenges that must be conquered to achieve the target of clinically relevant formulation in terms of safety, specificity and efficacy.


Citation: Saxena V (2014) RNAi-based Cancer Therapeutics: Are We There Yet?. J Pharmacovigil 2:153. doi: 10.4172/2329-6887.1000153

  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger